4-amino-N-(2(S)-hydroxy-propyl)-benzenesulfonamide | 444723-37-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-amino-N-(2(S)-hydroxy-propyl)-benzenesulfonamide
• 英文别名: 4-amino-N-[(2S)-2-hydroxypropyl]benzenesulfonamide
• CAS: 444723-37-9
• 化学式: C₉H₁₄N₂O₃S
• 分子量: 230.288
• InChiKey: GFNYRIDFMJEJDP-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  101
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-amino-N-(2(S)-hydroxy-propyl)-benzenesulfonamide 、 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 、 petrol 生成 NU 6139
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Cyclin dependent kinase inhibiting purine derivatives
  申请人：——

  公开号：US20040110775A1

  公开（公告）日：2004-06-10

  The present invention relates to a series of CDK-inhibiting purine derivatives of structural formula (I), or a pharmaceutically acceptable salt and/or prodrug form thereof, wherein: X is O, S or CHR X where R X is H or C 1-14 alkyl; D is NZ 1 Z 2 where Z 1 is selected from H, C 1-4 alkyl, C 1-4 hydroxyalkyl, an unsubstituted or substituted aryl or heteroaryl, and an unsubstituted or substituted aralkyl or heteroaralkyl group, and Z 2 is selected from an unsubstituted or substituted aryl or heteroaryl, and an unsubstituted or substituted aralkyl or heteroaralkyl group; A is selected from H, C 1-4 alkyl, C 1-4 alkoxy, hydroxy, CH 2 (CH 2 ) n OH (n=1-4), and NR a1 R a2 where R a1 and Ra 2 are each independently H or C 1-4 alkyl; B is selected from H, halo, C 1-4 alkyl, C 1-4 alkoxy, CF 3 , an optionally substituted aryl or an optionally substituted aralkyl, and a hydroxy group that may undergo a C═O tautomeric rearrangement; and Y comprises an unsubstituted or substituted 4- to 8-membered carbocyclic or heterocyclic ring, optionally forming part of a larger fused ring structure, or consists of an optionally substituted linear or branched hydrocarbon chain. These purine derivatives are potential chemotherapeutic agents and, accordingly, the present invention also relates to the use of these compounds in the treatment of tumours or other cell proliferation disorders and pharmaceutical compositions comprising these compounds.

  本发明涉及一系列CDK抑制嘌呤衍生物，其结构式（I），或其药学上可接受的盐和/或前药形式，其中：X为O、S或CHRX，其中RX为H或C1-14烷基；D为NZ1Z2，其中Z1选择自H、C1-4烷基、C1-4羟基烷基、未取代或取代的芳基或杂芳基，以及未取代或取代的芳基或杂芳基基团，Z2选择自未取代或取代的芳基或杂芳基，以及未取代或取代的芳基或杂芳基基团；A选择自H、C1-4烷基、C1-4烷氧基、羟基、CH2(CH2)nOH（n=1-4），和NRa1Ra2，其中Ra1和Ra2各自独立地为H或C1-4烷基；B选择自H、卤素、C1-4烷基、C1-4烷氧基、CF3、一个可选择取代的芳基或可选择取代的芳基基团，以及可能经历C=O互变异构重排的羟基；Y包括未取代或取代的4-至8-成员碳环或杂环，可选地构成更大的融合环结构的一部分，或由一个可选择取代的线性或支链烃链组成。这些嘌呤衍生物是潜在的化疗药物，因此，本发明还涉及将这些化合物用于治疗肿瘤或其他细胞增殖障碍的用途，以及包含这些化合物的药物组合物。
• CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES
  申请人：Cancer Research Technology Limited

  公开号：EP1353922A1

  公开（公告）日：2003-10-22
• [EN] CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES<br/>[FR] DERIVES DE PURINE INHIBANT LA KINASE DEPENDANTE DES CYCLINES
  申请人：CANCER RES CAMPAIGN TECH

  公开号：WO2002059125A1

  公开（公告）日：2002-08-01

  The present invention relates to a series of CDK-inhibiting purine derivatives of structural formula (I), or a pharmaceutically acceptable salt and/or prodrug form thereof, wherein: X is O, S or CHRx where Rx is H or C1-14 alkyl; D is NZ1Z2 where Z1 is selected from H, C1-4 alkyl, C1-4 hydroxyalkyl, an unsubstituted or substituted aryl or heteroaryl, and an unsubstituted or substituted aralkyl or heteroaralkyl group, and Z2 is selected from an unsubstituted or substituted aryl or heteroaryl, and an unsubstituted or substituted aralkyl or heteroaralkyl group; A is selected from H, C1-4 alkyl, C1-4 alkoxy, hydroxy, CH2(CH2)nOH (n=1-4), and NRalRa2 where Ral and Ra2 are each independently H or C1-4 alkyl; B is selected from H, halo, C1-4 alkyl, C1-4 alkoxy, CF3, an optionally substituted aryl or an optionally substituted aralkyl, and a hydroxy group that may undergo a C=O tautomeric rearrangement; and Y comprises an unsubstituted or substituted 4- to 8-membered carbocyclic or heterocyclic ring, optionally forming part of a larger fused ring structure, or consists of an optionally substituted linear or branched hydrocarbon chain. These purine derivatives are potential chemotherapeutic agents and, accordingly, the present invention also relates to the use of these compounds in the treatment of tumours or other cell proliferation disorders and pharmaceutical compositions comprising these compounds.